Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Figure 2

This illustration demonstrates the functional effects of dysregulated turnover of follicular proteoglycans on the growth and cycling behaviour of the hair follicles. As the ability of follicular cells to synthesise proteoglycans diminishes, the anagenic concentration of bioactive proteoglycans falls below a certain threshold leading to progressive degrees of follicular hypoglycania (FHG). Advanced FHG can result in a gradual increase in telogen to anagen duration ratios and decline in the maximum size of the hair follicles. At its early stages, FHG underlies subclinical alterations in the size of the follicle, called proteoglycan follicular hypotrophia (PFH), which advances to more significant stages, referred to as proteoglycan follicular atrophy (PFA). PFA is presented clinically as progressive hair miniaturisation.